INT36301

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 1987
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 3
Total Number 6
Disease Relevance 2.66
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleoplasm (TOP2A) nuclear chromosome (TOP2A) aging (TOP2A)
chromosome segregation (TOP2A) enzyme binding (TOP2A) DNA binding (TOP2A)
TOP2A (Homo sapiens)
Pain Link Frequency Relevance Heat
dexamethasone 3 38.56 Quite Low
eye pain 3 30.08 Quite Low
cva 3 27.52 Quite Low
headache 2 25.00 Low Low
Prostatitis 1 25.00 Low Low
Bioavailability 5 24.48 Low Low
Potency 6 5.00 Very Low Very Low Very Low
Central nervous system 5 5.00 Very Low Very Low Very Low
Inflammation 5 5.00 Very Low Very Low Very Low
corticosteroid 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Bacterial Respiratory Disease 47 99.78 Very High Very High Very High
Conjunctivitis 135 97.68 Very High Very High Very High
Death 6 94.24 High High
Bacterial Infection 6 90.92 High High
Sprains And Strains 18 86.12 High High
Mrsa Infection 32 83.48 Quite High
Pseudomonas Infection 3 82.96 Quite High
Infection 72 82.80 Quite High
Acquired Immune Deficiency Syndrome Or Hiv Infection 1 82.40 Quite High
Diabetes Mellitus 9 82.12 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Quinolone antimicrobials appear to inhibit DNA gyrase, an enzyme specific and essential for all bacteria, as their primary mechanism of action.
Negative_regulation (inhibit) of DNA gyrase associated with bacterial respiratory disease
1) Confidence 0.57 Published 1987 Journal Clin Pharm Section Abstract Doc Link 3311572 Disease Relevance 0.50 Pain Relevance 0
It has a uniquely balanced dual-targeting activity that inhibits both DNA gyrase and topoisomerase IV and is associated with a lower incidence of resistance development.
Negative_regulation (inhibits) of DNA gyrase
2) Confidence 0.03 Published 2010 Journal Clinical Ophthalmology (Auckland, N.Z.) Section Abstract Doc Link PMC2861926 Disease Relevance 0.40 Pain Relevance 0
Besifloxacin has a uniquely balanced dual-targeting activity that inhibits both DNA gyrase and topoisomerase IV and potentially hinders the rise of resistance.
Negative_regulation (inhibits) of DNA gyrase
3) Confidence 0.03 Published 2010 Journal Clinical Ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2861926 Disease Relevance 0.22 Pain Relevance 0
Fluoroquinolones act, with varying selectivities, through inhibition of the essential bacterial enzymes DNA gyrase and topoisomerase IV.11 In other words, they inhibit bacterial type II topoisomerases, leading to nonrepairable double-stranded DNA breaks and death of bacterial cells.
Negative_regulation (inhibition) of DNA gyrase associated with death
4) Confidence 0.02 Published 2010 Journal Clinical Ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2861926 Disease Relevance 0.53 Pain Relevance 0
Moxifloxacin acts by the same mechanism as other quinolones: inhibition of bacterial DNA gyrase (a Type II topoisomerase composed of two gyr A and two gyr B subunits) and topoisomerase IV (a heterotetramer made up of two par C and two par E subunits (Ruiz 2003; Mitscher 2005).
Negative_regulation (inhibition) of gyrase
5) Confidence 0.01 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1936362 Disease Relevance 0.42 Pain Relevance 0
Moxifloxacin may inhibit both DNA gyrase and Topoisomeras IV, but its mechanism of action is slightly different from that of other fluoroquinolones.
Spec (may) Negative_regulation (inhibit) of DNA gyrase
6) Confidence 0.01 Published 2007 Journal Clinical Interventions in Aging Section Body Doc Link PMC2684507 Disease Relevance 0.58 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox